Gene therapy for hemophilia B is an innovative treatment approach that aims to correct the genetic defect causing the disorder. In hemophilia B, individuals have a deficiency in clotting factor IX, a protein crucial for blood clotting. Gene therapy delivers a functioning copy of the faulty gene directly to the liver cells using a modified virus, allowing the body to produce its own factor IX. This treatment can significantly reduce or even eliminate the need for regular factor replacement therapy, offering improved quality of life and fewer bleeding episodes for people with hemophilia B.